\
&
Contact us
\
&
Contact us
Published on | 7 months ago
ProgrammesIn the context of simplification, the Commission has introduced the following substantial changes in the Standard Application Form (Version 5.0) for Horizon Europe Research & Innovation Actions (RIA) and Innovation Actions (IA) and Coordination and Support Actions (CSA):
Note that the revised templates are applicable for the 2026 and 2027 call topics.
!Please do keep in mind that the correct template to be used as an applicant to a specific call topic is always the one linked to this topic in the submission system!
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Climate, Energy, Mobility Agro-Food, Environment
Abstract submission and registration are open for the first European Partnership on Animal Health and Welfare Scientific Conference. The event is set to take place in Milan, Italy, from 19 to 22 January 2027 and invites contributions from both EUP AH&W members and non-members. Abstracts are due by 31 August 2026. The conference is designed to... read more
Digital, Industry & Space Agro-Food, Environment
The 2nd EO 4 Soil Symposium is organised by the European Space Agency (ESA) and focusses on three thematic areas: policy and user uptake scientific and technical progress applications and use cases Topics include soil monitoring methods, soil organic carbon mapping, uncertainty assessment, data harmonisation, soil carbon certific... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
